Prevail Therapeutics Inc.
(NASDAQ GS: PRVL)
Rigrodsky Law, P.A. is investigating Prevail Therapeutics Inc. (“Prevail”) regarding possible breaches of fiduciary duties and other violations of law related to Previal's agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Prevail’s shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.